A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease
This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks: Who can join: Adults with early-stage Parkinson's disease on stable medication regimens. What participants do: * Take their assigned dose twice daily (morning and evening) for 12 weeks. * Visit the clinic at baseline and weeks 4, 8, and 12 for blood tests (including hypoxanthine), exams, and questionnaires. * Keep a simple diary of any side effects or changes in daily activities. Risks and benefits: Possible side effects include mild gastrointestinal upset, headache, or elevated uric acid levels. While direct benefit is not guaranteed, this safety data will inform future Parkinson's disease treatments. Learn more: Contact \[site-specific contact info\] for details on eligibility and enrollment.
• Able to provide voluntary written informed consent.
• Receiving stable Parkinson's disease medication (no changes in type or dose) for at least 3 months before enrollment.
• Age 18 to 80 years at the time of consent.
• Diagnosed with Parkinson's disease by a specialist according to MDS-PD diagnostic criteria, and at pre-enrollment screening, all of the following are met:
‣ Hoehn-Yahr stage (ON state) 1 to 3
⁃ MDS-UPDRS Part III (ON state) score 10 to 35
⁃ Mini-Mental State Examination (MMSE) score ≥ 24